Drugs / Liver-enriched antimicrobial peptide 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04043065 | Jan → May 2019 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liver-enriched antimicrobial peptide 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04043065 ↗ |
| Known as | LEAP-2 | “a predicted sequence of liver-enriched antimicrobial peptide 2 (LEAP-2) was shown to induce a glucose-stimulated insulin secretion” NCT04043065 ↗ |
| Modality | Peptide | “LEAP-2 is an endogenous circulating peptide” NCT04043065 ↗ |
| Route | Other | “Infusion of LEAP-2 during a 180 min grated glucose infusion.” NCT04043065 ↗ |